The panel discussion and vote regarding radiosensitizing chemotherapy regimens for bladder-preserving chemoradiation following a maximal TURBT led to the addition of "cisplatin and paclitaxel" as a category 2B recommendation.

Panel discussion comment to add a new section for "Radiosensitizing chemotherapy given concurrently with conventionally fractionated radiation for palliation of metastases or for pelvic recurrence after cystectomy.”